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* Background: Based on multiple studies, the use of a glycoprotein IIb/IIIa inhibitor (GPI) in the setting of acute coronary syndrome (ACS) is 
associated with lower major ischemic events, as well as decreased death rate, MI, and need for urgent revascularization. Furthermore, these studies 
have defined the incidence of bleeding with GPIs, as well as the incidence of bleeding with GPIs plus a 300 mg clopidogrel load. We hypothesized 
that in the setting of a 600 mg clopidogrel load, patients who receive a GPI will have an increased incidence of bleeding. 
Methods and Results: Using registry data, we analyzed 638 ACS patients who received a GPI plus clopidogrel. Patients were divided into either 
a 600 mg clopidogrel loading dose group or a 300 mg clopidogrel loading dose group. We compared registry specific bleeding endpoints between 
the two groups. Baseline characteristics were similar between the two groups, although there were more STEMI patients in the 600 mg clopidogrel 
group. For the entire cohort there was no statistically significant difference in bleeding between the two groups (table 1). When patients were 
propensity matched according to age, gender, BMI, creatinine, and a presenting diagnosis of STEMI, there was a statistically significant increase in 
gastrointestinal bleeding in patients who received a 300 mg clopidogrel load (table 1). 
Conclusions: In 638 ACS patients that presented to the Cleveland Clinic and received a GPI, a 600 mg clopidogrel loading dose did not increase 
the incidence of bleeding.
 
